Infinity Pharmaceuticals, Inc. Form 8-K: Current report
Filings on SEC EDGAR, newest first; amendments sit with their base form. Values are as filed.
- 2009-12-07: Form 8-K; Period of report 2009-12-02; Description 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers; Details 5.02.
- 2009-12-01: Form 8-K; Period of report 2009-12-01; Description 7.01 Regulation FD Disclosure; Details 7.01.
- 2009-11-16: Form 8-K; Period of report 2009-11-16; Description 7.01 Regulation FD Disclosure; Details 7.01.
- 2009-11-09: Form 8-K; Period of report 2009-11-09; Description 2.02 Results of Operations and Financial Condition; Details 2.02.
| Filed | Form | Period of report | Description | Details | Document |
|---|---|---|---|---|---|
| 2009-12-07 | 8-K | 2009-12-02 | 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers | 5.02 On December 2, 2009, our Board of Directors promoted Adelene Q. Perkins to Chief Executive Officer and appointed Ms. Perkins as a director, both effective January 1, 2010. | d8k.htm |
| 2009-12-01 | 8-K | 2009-12-01 | 7.01 Regulation FD Disclosure | 7.01 From time to time, we intend to conduct meetings with third parties in which our current corporate slide presentation is presented. | d8k.htm |
| 2009-11-16 | 8-K | 2009-11-16 | 7.01 Regulation FD Disclosure | 7.01 From time to time, we intend to conduct meetings with third parties in which our current corporate slide presentation is presented. | d8k.htm |
| 2009-11-09 | 8-K | 2009-11-09 | 2.02 Results of Operations and Financial Condition | 2.02 On November 9, 2009, we issued a press release announcing our results for the quarter ended September 30, 2009 and will conduct a previously-announced, publicly-available conference call to discuss those results. | d8k.htm |
| 2009-10-07 | 8-K | 2009-10-06 | 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers | 5.02 (d) On October 6, 2009, our Board of Directors appointed Thomas J. Lynch, Jr., M.D. as a director and to the Research and Development Committee of the Board. | d8k.htm |
| 2009-09-09 | 8-K | 2009-09-08 | 7.01 Regulation FD Disclosure | 7.01 From time to time, we intend to conduct meetings with third parties in which our current corporate slide presentation is presented. | d8k.htm |
| 2009-08-06 | 8-K | 2009-08-05 | 2.02 Results of Operations and Financial Condition | 2.02 On August 5, 2009, we issued a press release announcing our results for the quarter ended June 30, 2009 and will conduct a previously-announced, publicly-available conference call to discuss those results. | d8k.htm |
| 2009-06-01 | 8-K | 2009-05-30 | 8.01 Other Events | 8.01 On May 30, 2009, we issued a press release announcing preliminary data from the Phase 2 portion of a study of IPI-504 in patients with advanced non-small cell lung cancer and a Phase 1 study of IPI-504 in combination with Taxotere® (docetaxel). | d8k.htm |
| 2009-05-05 | 8-K | 2009-05-04 | 2.02 Results of Operations and Financial Condition | 2.02 On May 4, 2009, we issued a press release announcing our results for the quarter ended March 31, 2009 and will conduct a previously-announced, publicly-available conference call to discuss those results. | d8k.htm |
| 2009-04-21 | 8-K | 2009-04-15 | 2.02 Results of Operations and Financial Condition | 2.02 On April 15, 2009, we issued a press release in which we stated that we anticipate announcing that we ended the first quarter of 2009 with approximately $153 million in cash, cash equivalents and available-for-sale securities. | d8k.htm |
| 2009-04-15 | 8-K | 2009-04-15 | 8.01 Other Events | 8.01 On April 15, 2009, we announced that we have terminated our phase 3 clinical trial of IPI-504 in gastrointestinal stromal tumors. | d8k.htm |
| 2009-03-26 | 8-K | 2009-03-23 | 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers | 5.02 Additional information regarding the compensation of our directors and executive officers will be included in our proxy statement to be filed in connection with our annual meeting of stockholders to be held in June 2009. | d8k.htm |
| 2009-03-17 | 8-K | 2009-03-12 | 5.03 Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year | 5.03 (i) amend the provisions related to the advance notice that stockholders must give to the corporation to properly bring business before an annual meeting of stockholders, which provisions now provide that for any such notice to be timely, it must be received by the corporation not later than the close of business on the 90th day, nor earlier than the close of business on the 120th day, prior to the first anniversary of the preceding year’s annual meeting. | d8k.htm |
| 2009-02-09 | 8-K | 2009-02-09 | 2.02 Results of Operations and Financial Condition | 2.02 On February 9, 2009, we issued a press release announcing our results for the quarter and year ended December 31, 2008 and will conduct a previously-announced, publicly-available conference call to discuss those results. | d8k.htm |
| 2009-02-03 | 8-K | 2009-01-29 | 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers | 5.02 (b) On January 29, 2009, Vicki L. Sato informed us that she will retire from our Board of Directors effective the date of our 2009 annual stockholder meeting, which we anticipate will take place in June 2009. | d8k.htm |
| 2009-01-12 | 8-K | 2009-01-12 | 7.01 Regulation FD Disclosure; 8.01 Other Events | 7.01 From time to time, we intend to conduct meetings with third parties in which our current corporate slide presentation is presented. 8.01 On January 12, 2009, we issued a press release announcing our 2009 and long-term corporate goals. | d8k.htm |
| 2009-01-08 | 8-K | 2009-01-07 | 3.02 Unregistered Sales of Equity Securities | 3.02 On January 7, 2009, pursuant to a Securities Purchase Agreement (the “Agreement”) dated November 19, 2008 between Purdue Pharma L.P. and Purdue Pharmaceutical Products L.P. (collectively, the “Purchasers”) and Infinity Pharmaceuticals, Inc. (“Infinity”), Infinity issued and sold to the Purchasers an aggregate of 2,000,000 shares (the “Second Closing Shares”) of our common stock, $0.001 par value per share (the “Common Stock”), and warrants to purchase up to an aggregate of 6,000,000 shares of Common Stock (the “Warrants”), for an aggregate purchase price of $30,000,000. | d8k.htm |